Next Article in Journal
Prevalence of Human T Cell Lymphotropic Virus 1 Infection in Canada
Previous Article in Journal
Clinical Trial Implications for Study Participants Accessing Medical Assistance in Dying
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4385
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Secondary Polycythemia in a Sarcoma Patient: A Commentary about Cediranib

by
A. Awan
and
Thierry Alcindor
*
McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 1-2; https://doi.org/10.3747/co.26.4385
Submission received: 3 November 2018 / Revised: 6 December 2018 / Accepted: 12 January 2019 / Published: 1 February 2019

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Cediranib, a potent inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor subunit B, and the c-Kit receptor tyrosine kinase, has shown antitumour activity as an antiangiogenic agent in preclinical models. Initial clinical trials with cediranib in a variety of tumour types, including glioblastoma multiforme, non-small-cell lung cancer, renal cell cancer, colorectal cancer, and prostate cancer, showed activity comparable to that for other vascular endothelial growth factor (vegf) inhibitors, but with significant toxicities, resulting in abandonment of the drug’s development in 2011. [...]

Share and Cite

MDPI and ACS Style

Awan, A.; Alcindor, T. Secondary Polycythemia in a Sarcoma Patient: A Commentary about Cediranib. Curr. Oncol. 2019, 26, 1-2. https://doi.org/10.3747/co.26.4385

AMA Style

Awan A, Alcindor T. Secondary Polycythemia in a Sarcoma Patient: A Commentary about Cediranib. Current Oncology. 2019; 26(1):1-2. https://doi.org/10.3747/co.26.4385

Chicago/Turabian Style

Awan, A., and Thierry Alcindor. 2019. "Secondary Polycythemia in a Sarcoma Patient: A Commentary about Cediranib" Current Oncology 26, no. 1: 1-2. https://doi.org/10.3747/co.26.4385

APA Style

Awan, A., & Alcindor, T. (2019). Secondary Polycythemia in a Sarcoma Patient: A Commentary about Cediranib. Current Oncology, 26(1), 1-2. https://doi.org/10.3747/co.26.4385

Article Metrics

Back to TopTop